ClinVar Miner

Submissions for variant NM_004360.5(CDH1):c.546A>C (p.Lys182Asn)

gnomAD frequency: 0.00001  dbSNP: rs201141645
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen CDH1 Variant Curation Expert Panel RCV003328203 SCV001943335 benign CDH1-related diffuse gastric and lobular breast cancer syndrome 2023-08-10 reviewed by expert panel curation The c.546A>C (p.Lys182Asn) variant has an allele frequency of 0.00104 (>0.1%, 9 out of 8628 alleles) in the East Asian subpopulation of the ExAC cohort (BS1). The variant has also been observed in >10 (56) individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; SCV000637839.5; SCV000566004.5). Therefore, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS1, BS2.
Ambry Genetics RCV000129061 SCV000183762 benign Hereditary cancer-predisposing syndrome 2021-11-05 criteria provided, single submitter clinical testing This alteration is classified as benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
GeneDx RCV000485548 SCV000566004 likely benign not provided 2021-01-19 criteria provided, single submitter clinical testing Observed in individuals with diffuse gastric cancer (Cho 2017); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Observed in 0.008% (20/251196 alleles) in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 28522256, 31159747, 32426482, 33309985, 32241597)
Invitae RCV001081944 SCV000637839 likely benign Hereditary diffuse gastric adenocarcinoma 2024-01-29 criteria provided, single submitter clinical testing
GeneKor MSA RCV000129061 SCV000821978 uncertain significance Hereditary cancer-predisposing syndrome 2018-08-01 criteria provided, single submitter clinical testing
Color Diagnostics, LLC DBA Color Health RCV000129061 SCV000903227 benign Hereditary cancer-predisposing syndrome 2016-03-25 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001844046 SCV002103745 benign not specified 2022-02-03 criteria provided, single submitter clinical testing Variant summary: CDH1 c.546A>C (p.Lys182Asn) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 8e-05 in 251196 control chromosomes, predominantly at a frequency of 0.00082 within the East Asian subpopulation in the gnomAD database. The observed variant frequency within East Asian control individuals in the gnomAD database is approximately 39 fold of the estimated maximal expected allele frequency for a pathogenic variant in CDH1 causing Breast Cancer phenotype (2.1e-05), strongly suggesting that the variant is a benign polymorphism found primarily in populations of East Asian origin. To our knowledge, no occurrence of c.546A>C in individuals affected with Breast Cancer and no experimental evidence demonstrating its impact on protein function have been reported. Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments (Benign n=2, likely benign n=2, VUS n=2). Based on the evidence outlined above, the variant was classified as benign.
Sema4, Sema4 RCV000129061 SCV002529193 uncertain significance Hereditary cancer-predisposing syndrome 2021-08-04 criteria provided, single submitter curation
Department of Pathology and Laboratory Medicine, Sinai Health System RCV001354143 SCV001548685 uncertain significance Malignant tumor of breast no assertion criteria provided clinical testing The CDH1 p.Lys182Asn variant was not reported in the literature as identified in an affected population. The variant was identified in dbSNP (ID: rs201141645 as "With Likely benign, Uncertain significance allele") and ClinVar (3x as uncertain significance by Ambry Genetics, GeneDx, and Invitae). The variant was not identified in Cosmic, MutDB, or Zhejiang University databases. The variant was identified in control databases in 21 of 276982 chromosomes at a frequency of 0.00007 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: East Asian in 15 of 18866 chromosomes (freq: 0.0008), Other in 1 of 6466 chromosomes (freq: 0.0002), European in 1 of 126514 chromosomes (freq: 0.000008), and South Asian in 4 of 30780 chromosomes (freq: 0.0001), while the variant was not observed in the African, Latino, Ashkenazi Jewish, or Finnish populations. One aggregation assay showed that the Lys182Asn variant behaved similarly to the wildtype protein in CHO cells (Cho 2017). The p.Lys182 residue is not conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and only 1 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing; this is not very predictive of pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.